Species differences of inhibitory effects on P-glycoprotein-mediated drug transport

Journal of Pharmaceutical Sciences

Volumn 96, Issue 6, 2007, Pages 1609-1618

  Suzuyama, Naoto ^a   Katoh, Miki ^a   Takeuchi, Toshiyuki ^b   Yoshitomi, Sumie ^b   Higuchi, Tomoaki ^b   Asashi, Satoru ^b   Yokoi, Tsuyoshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Drug interaction; Drug transporter; Inhibition; Multidrug resistance transporters; P glycoprotein; Species differences

Indexed keywords

CYCLOSPORIN; DAUNORUBICIN; DIGOXIN; GLYCOPROTEIN P; QUINIDINE; VERAPAMIL;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOG; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TRANSPORT; HUMAN; HUMAN CELL; IC 50; MONKEY; MOUSE; NONHUMAN; PROTEIN INTERACTION; RAT; SPECIES DIFFERENCE;

EID: 34250763702     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20787     Document Type: Article

References (29)

1. Juliano RL, Ling V. 1976. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455: 152-162.
2. Senior AE, Gadsby DC. 1997. ATP hydrolysis cycles and mechanism in P-glycoprotein and CFTR. Semin Cancer Biol 8:143-150.
3. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. 1999. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361-398.
4. 1). J Phamacol Exp Ther 263:840-845.
5. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. 1987. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84:7735-7738.
6. Bussey HI. 1982. The influence of quinidine and other agents on digitalis glycosides. Am Heart J 104:289-302.
7. Verschraagen M, Koks CH, Schellens JH, Beijnen JH. 1999. P-glycoprotein system as a determinant of drug interactions: The case of digoxin-verapamil. Pharmacol Res 40:301-306.
8. Tsuji A. 2002. Transporter-mediated drug interactions. Drug Metab Pharmacokinet 17:253-274.
9. Katoh M, Suzuyama N, Takeuchi T, Yoshitomi S, Asahi S, Yokoi T. 2006. Kinetic analyses for species differences in P-glycoprotein-mediated drug transport. J Pharm Sci, in press.
10. 1. Pharm Res 23:1460-1472.
11. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. 1951. Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
12. Lin JH, Yamazaki M. 2003. Role of P-glycoprotein in pharmacokinetics: Clinical implications. Clin Pharmacokinet 42:59-98.
13. Schinkel AH, Jonker JW. 2003. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: An overview. Adv Drug Deliv Rev 55:3-29.
14. Pedersen KE. 1985. Digoxin interactions. The influence of quinidine and verapamil on the pharmacokinetics and receptor binding of digitalis glycosides. Acta Med Scand Suppl 697:1-40.
15. Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, Kim RB. 2000. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 28:655-660.
16. Cardarelli CO, Aksentijevich I, Pastan I, Gottesman MM. 1995. Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters. Cancer Res 55:1086-1091.
17. Balimane PV, Patel K, Marino A, Chong S. 2004. Utility of 96 well Caco-2 cell system for increased throughput of P-gp screening in drug discovery. Eur J Pharm Biopharm 58:99-105.
18. Hori R, Okamura N, Aiba T, Tanigawara Y. 1993. Role of P-glycoprotein in renal tubular secretion of digoxin in the isolated perfused rat kidney. J Pharmacol Exp Ther 266:1620-1625.
19. Katoh M, Nakajima M, Yamazaki H, Yokoi T. 2000. Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: Comparison with the effects on CYP3A4. Pharm Res 17:1189-1197.
20. Tang-Wai DF, Kajiji S, DiCapua F., de Graaf D, Roninson IB, Gros P. 1995. Human (MDR1) and mouse (mdr1, mdr3) P-glycoproteins can be distinguished by their respective drug resistance profiles and sensitivity to modulators. Biochemistry 34:32-39.
21. Isenberg B, Thole H, Tummler B, Demmer A. 2001. Identification and localization of three photobinding sites of iodoarylazidoprazosin in hamster P-glycoprotein. Eur J Biochem 268:2629-2634.
22. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. 2003. P-glycoprotein: From genomics to mechanism. Oncogene 22:7468-7485.
23. Yang CP, Cohen D, Greenberger LM, Hsu SI, Horwitz SB. 1990. Differential transport properties of two mdr gene products are distinguished by progesterone. J Biol Chem 265:10282-10288.
24. 939/941. Biochemistry 33:5041-5048.
25. Arceci RJ, Croop JM, Horwitz SB, Housman D. 1988. The gene encoding multidrug resistance is induced and expressed at high levels during pregnancy in the secretory epithelium of the uterus. Proc Natl Acad Sci USA 85:4350-4354.
26. Teeter LD, Estes M, Chan JY, Atassi H, Sell S, Becker FF, Kuo MT. 1993. Activation of distinct multidrug-resistance (P-glycoprotein) genes during rat liver regeneration and hepatocarcinogenesis. Mol Carcinog 8:67-73.
27. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HP, Berns AJ, Borst P. 1994. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502.
28. Keogh JP, Kunta JR. 2006. Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein. Eur J Pharm Sci 27:543-554.
29. Kakumoto M, Sakaeda T, Takara K, Nakamura T, Kita T, Yagami T, Kobayashi H, Okamura N, Okumura K. 2003. Effects of carvedilol on MDR1-mediated multidrug resistance: Comparison with verapamil. Cancer Sci 94:81-86.